secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-048738
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q4 rev $207M (+25%), net loss $129M; restructures 10% headcount; UX111 gets IRL
--------------------------------------------------------------------------------

- Full year 2025 total revenue $673M (+20% YoY); Crysvita $481M, Dojolvi $96M, Evkeeza $59M.
- Q4 net loss $129M ($1.29/share); full year net loss $575M ($5.83/share).
- Restructuring: 10% workforce cut (~130 employees), $50M charges; path to profitability in 2027.
- 2026 revenue guidance $730-760M; combined R&D+SG&A expenses flat to down low-single digits.
- UX111 BLA resubmitted; received Incomplete Response Letter requesting additional CMC documentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/0001193125-26-048738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-048738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer